Nautilus Biotechnology, Inc. — Form 10-Q
Filed July 28, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Sujal Patel (CEO) and Anna Mowry (CFO) certified the Q2 2026 10-Q for period ended June 30, 2026, dated July 28, 2026. Both officers attested that financial statements fairly present the company's financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses or fraud disclosures were noted.
Why this rating
Routine Sarbanes-Oxley certification exhibits; standard required disclosure with no substantive business, financial, or operational content
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.